Intermediate versus hard end points in clinical trials on hypertension

Area of Science:

• Cardiology
• Clinical Trials
• Hypertension Management

Background:

• Randomized clinical trials (RCTs) are crucial for evaluating hypertension treatments.
• Assessing treatment efficacy requires careful consideration of outcome measures.
• Both clinical events and surrogate markers are used in hypertension RCTs.

Purpose of the Study:

• To review the key features of RCTs in hypertension treatment.
• To compare the use of clinical events versus surrogate outcome measures.
• To analyze the advantages, limitations, and clinical relevance of each outcome assessment method.

Main Methods:

• Literature review of published randomized clinical trials in hypertension.
• Analysis of studies utilizing clinical event outcomes (e.g., stroke, myocardial infarction).
• Analysis of studies employing surrogate outcome measures (e.g., blood pressure reduction).

Main Results:

• Clinical event-based trials provide definitive evidence of treatment benefit but require large sample sizes and long follow-up.
• Surrogate outcome trials offer faster results and require smaller sample sizes but may not always correlate with clinical benefit.
• Both approaches have distinct advantages and limitations in assessing hypertension therapies.

Conclusions:

• The choice between clinical events and surrogate outcomes in hypertension trials depends on research questions, resources, and desired certainty.
• Understanding the strengths and weaknesses of each method is vital for interpreting trial results and guiding clinical practice.
• Future hypertension research should strategically employ both outcome measures to optimize treatment evaluation.